The ECOG-ACRIN E2100 study is a pivotal clinical trial conducted by the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN). It primarily focused on evaluating the efficacy and safety of combining the anti-angiogenic agent bevacizumab with the chemotherapeutic drug paclitaxel in patients with metastatic breast cancer.
